Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0081004 |
| Name | high-grade B-cell lymphoma double-hit/triple-hit |
| Definition | A large B-cell lymphoma that is characterized by the abnormal rearrangement of two genes, MYC gene and either BCL2 or BCL6 genes. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma large B-cell lymphoma high-grade B-cell lymphoma double-hit/triple-hit |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03696784 | Phase I | Rimiducid Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK | Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | Active, not recruiting | USA | 0 |
| NCT04002947 | Phase II | Acalabrutinib + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma | Recruiting | USA | 0 |
| NCT04231877 | Phase I | Cyclophosphamide + Doxorubicin + Etoposide + Glofitamab-gxbm + Polatuzumab vedotin-piiq + Prednisone + Rituximab | Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma | Recruiting | USA | 0 |
| NCT04479267 | Phase II | Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisolone + Rituximab Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab Cyclophosphamide + Doxorubicin + Methylprednisolone + Polatuzumab vedotin-piiq + Rituximab | Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma | Active, not recruiting | USA | 0 |
| NCT04855253 | Phase Ib/II | E7777 | Study of E7777 Prior to Kymriah for R/R DLBCL | Recruiting | USA | 0 |
| NCT04970901 | Phase I | Obinutuzumab Loncastuximab tesirine-lpyl + Mosunetuzumab-axgb Loncastuximab tesirine-lpyl + Polatuzumab vedotin-piiq Glofitamab-gxbm + Loncastuximab tesirine-lpyl | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | Recruiting | USA | ITA | GBR | ESP | CZE | BEL | 0 |
| NCT05400109 | Phase I | Cyclophosphamide + Fludarabine UF-KURE19 | Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas | Recruiting | USA | 0 |
| NCT05507541 | Phase II | Pembrolizumab + TTI-622 Pembrolizumab + TTI-621 | TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Active, not recruiting | USA | 0 |
| NCT05600686 | Phase II | Cyclophosphamide + Doxorubicin + Etoposide + Loncastuximab tesirine-lpyl + Prednisone + Rituximab + Vincristine Sulfate | Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma | Recruiting | USA | 0 |
| NCT05641428 | Phase II | axicabtagene ciloleucel ARI-0001 | Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL (HOVON161) | Recruiting | NLD | 0 |
| NCT05664217 | Phase II | NKTR-255 | NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma | Terminated | USA | 0 |
| NCT05755087 | Phase I | Tegavivint | Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma | Recruiting | USA | 0 |
| NCT05852717 | Phase II | Cisplatin + Dexamethasone + Epcoritamab-bysp + Gemcitabine | Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma | Recruiting | USA | 0 |
| NCT05929716 | Phase II | Magrolimab + Rituximab | An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma | Withdrawn | 0 | |
| NCT05989204 | Phase I | HuCART19-IL18 | TmCD19-IL18 in CD19+ Cancers | Recruiting | USA | 0 |
| NCT06045247 | Phase II | Cyclophosphamide + Epcoritamab-bysp + Prednisone + Rituximab + Vincristine Sulfate | Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | Recruiting | USA | 0 |
| NCT06088654 | Phase Ib/II | IPH6501 | Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | FRA | AUS | 0 |
| NCT06090539 | Phase I | BMS-986458 + Rituximab BMS-986458 BMS-986458 + Mosunetuzumab-axgb BMS-986458 + Glofitamab-gxbm + Obinutuzumab | A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas | Recruiting | USA | NLD | FRA | ESP | DEU | CHE | 0 |
| NCT06248086 | Phase I | ASP101G + ASP2802 | A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas | Terminated | AUS | 0 |
| NCT06287398 | Phase II | Epcoritamab-bysp Cytarabine + Dexamethasone + Epcoritamab-bysp + Oxaliplatin + Rituximab | Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL | Recruiting | AUS | 0 |
| NCT06649812 | Phase II | Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax | Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma | Recruiting | USA | 0 |
| NCT06788964 | Phase II | Loncastuximab tesirine-lpyl + Rituximab | Loncastuximab Tesirine and Rituximab as Bridging Therapy Prior to Standard-of-care CD19 CAR T-cell Therapy in Patients With Large B-cell Lymphoma (CORAL) | Recruiting | USA | 0 |
| NCT06905509 | Phase II | Cytarabine + Dexamethasone + Epcoritamab-bysp + Oxaliplatin + Rituximab Epcoritamab-bysp + Gemcitabine + Oxaliplatin Carboplatin + Cytarabine + Dexamethasone + Epcoritamab-bysp + Rituximab Carboplatin + Epcoritamab-bysp + Etoposide + Ifosfamide + Rituximab | Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | Recruiting | USA | 0 |
| NCT06918912 | Phase II | Loncastuximab tesirine-lpyl | Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure (LORELY) | Recruiting | ITA | 0 |
| NCT06919939 | Phase II | Epcoritamab-bysp + Loncastuximab tesirine-lpyl | Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma (EPCOR+LONCA) | Not yet recruiting | USA | 0 |
| NCT06977711 | Phase I | Loncastuximab tesirine-lpyl + Rituximab + Roflumilast Cyclophosphamide + Doxorubicin + Loncastuximab tesirine-lpyl + Prednisone + Rituximab + Vincristine Sulfate | Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL) | Recruiting | USA | 0 |
| NCT07042438 | Phase II | Fecal microbiota axicabtagene ciloleucel + Fecal microbiota | Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells | Not yet recruiting | USA | 0 |
| NCT07082803 | Phase I | TLN-121 + TLN-254 TLN-121 | TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas | Recruiting | USA | AUS | 0 |
| NCT07097363 | Phase II | Cyclophosphamide + Doxorubicin + Epcoritamab-bysp + Etoposide + Prednisone + Rituximab | Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma | Not yet recruiting | USA | 0 |
| NCT07123454 | Phase Ib/II | AZD4512 | A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (Lumi-NHL) | Recruiting | USA | ITA | GBR | AUS | 3 |
| NCT07166549 | Phase I | Anti-CD19-CD20 CAR T cells | Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial) (BaseCAR-01) | Not yet recruiting | CHE | 0 |
| NCT07197307 | Phase II | Epcoritamab-bysp + Loncastuximab tesirine-lpyl | Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) (CLEAR) | Not yet recruiting | DEU | 0 |
| NCT07225439 | Phase I | Aldesleukin + Rituximab + Tafasitamab-cxix Cyclophosphamide + Fludarabine | Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | Not yet recruiting | USA | 0 |
| NCT07226843 | Phase I | LY4584180 + Rituximab LY4584180 | A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers | Not yet recruiting | USA | 0 |
| NCT07254754 | Phase II | axicabtagene ciloleucel | Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma (LATE-R-GEL-23) | Recruiting | ESP | 0 |